Q-omics provides the consensus-scored GRXCR2 profile across patient tissues and cancer cell-line models. GRXCR2 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, GRXCR2 is differentially expressed in 8, with the highest sampling consensus in BRCA. Additionally, GRXCR2 RNA expression shows 7,402 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, BRCA, and THYM as cancer lineages where GRXCR2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GRXCR2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GRXCR2 survival associations across molecular data types. GRXCR2 RNA expression shows survival associations in the most cancer types (15), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GRXCR2 RNA expression–survival associations across cancer types. High GRXCR2 expression shows unfavorable associations in ACC, KIRC, BLCA and HNSC, but favorable associations in UCS and STAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for GRXCR2 RNA expression.
This table summarizes GRXCR2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for GRXCR2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GRXCR2 shows lower tumor expression in BRCA, THCA, KIRP and COAD and higher tumor expression in LUSC and PRAD. The BRCA box plot shows higher GRXCR2 RNA expression in normal versus tumor tissue (log2 FC = −0.158, t-test p < 0.001).
This table shows molecular features associated with GRXCR2 in patient tissues and cancer cell lines. In patient samples, GRXCR2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, GRXCR2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and UPPER_AERODIGESTIVE_TRACT.
